Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma

Saved in:
Bibliographic Details
Published inJournal of Clinical Oncology Vol. 38; p. 10034
Main Authors Dummer, Reinhard, Biette, Kelly, Gusenleitner, Daniel, Ramesh, Radha, Lebbe, Celeste, Atkinson, Victoria, Mandalà, Mario, Nathan, Paul D., Arance, Ana, Richtig, Erika, Yamazaki, Naoya, Robert, Caroline, Schadendorf, Dirk, Tawbi, Hussein Abdul-Hassan, Ascierto, Paolo Antonio, Ribas, Antoni, Flaherty, Keith, Gasal, Eduard, Brase, Jan C., Long, Georgina V.
Format Journal Article
LanguageJapanese
Published American Society of Clinical Oncology (ASCO) 20.05.2020
Subjects
Medizin
Online AccessGet full text
ISSN0732-183X
1527-7755
DOI10.1200/jco.2020.38.15_suppl.10034

Cover

More Information
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2020.38.15_suppl.10034